Navigation Links
Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
Date:12/6/2012

bodes well for the future success of GLYX-13 and the other promising compounds we have generated from this platform." 

Other NMDA receptor-modulating agents, such as ketamine, have been shown in several human clinical trials to act very rapidly to alleviate the symptoms of depression and bipolar disorder, but their clinical utility has been hampered by their potential for abuse and behavioral impairment, including schizophrenia-like effects at therapeutic doses.

"We are encouraged by these promising data," noted Ronald M. Burch, MD, PhD, Chief Medical Officer of Naurex.  "We have recently begun dosing patients in a GLYX-13 Phase Ilb repeated dose trial, and we are on track to advance our second-generation oral compound, NRX-1074, into clinical trials next year.  Preclinical studies show that our novel NMDA modulators may be applicable to a number of CNS disorders, and we look forward to assessing their potential to address major unmet needs in psychiatry and neurology."

The Phase Ila trial was a randomized, double blind, placebo-controlled study of the efficacy and safety of a single dose of intravenous GLYX-13 in subjects who had failed at least one other antidepressant during the current depressive episode.  It was conducted at 12 clinical centers in the U.S.  Outcome measures included ratings of signs, symptoms and changes in depression scores on standard rating scales for mood and psychiatric disorders.  Independent raters from MedAvante, who were blinded to the protocol, administered certain psychiatric assessments for the trial to ensure the quality and objectivity of the screening and rating data.  Safety was also assessed.

Naurex's CNS programs are based on the work of company founder, Joseph R. Moskal, PhD, and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.

The 51st Annual Meeting of the American College of Neuropsychopharmacology i
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
8. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
9. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... CITY, Calif., Sept. 13 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, CEO ... LLC Sixth Annual San,Francisco Institutional Investor Forum Conference ... Time at The Ritz-Carlton Hotel in San Francisco. ...
... JOSE, Calif., Sept. 13 Micrus,Endovascular Corporation (Nasdaq: ... of Stockholders will be broadcast live over the,Internet on ... (9:00,a.m. Pacific time). Those listening to the meeting via ... ask questions during the,meeting. What: Micrus Endovascular ...
... Exchange Agreement, COPENHAGEN, September 13 Genmab ... asset exchange agreement with,Medarex, Inc. Under the terms ... HuMax-Inflam(TM)/MDX-018, which targets IL-8, and Medarex will,receive full ... and,Medarex will release to each other all previously ...
Cached Biology Technology:Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders 2Genmab Announces Asset Exchange Agreement 2
(Date:4/17/2014)... ALBUQUERQUE, N.M. A credit-card-sized anthrax detection cartridge developed ... small business makes testing safer, easier, faster and cheaper. ... causes anthrax, is commonly found in soils all over ... illness in both humans and animals. The bacteria can ... to B. anthracis may occur through skin ...
(Date:4/17/2014)... German . Our ... provide us with a continuous stream of information about our ... still in a car the world glides by us ... without effort, our brain calculates self-motion from this "optic flow". ... steady gaze during our own movements. Together with biologists from ...
(Date:4/17/2014)... Stem cells in bone marrow need to produce hydrogen ... tissue, according to a new study from the Center ... of Dentistry of USC. , Professor Songtao Shi, principal ... sulfide produced by the cells governs the flow of ... cellular signals that results in osteogenesis, or the creation ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... researchers have discovered how the brain creates a scent symphony ... mice, the researchers found that nerve cells in the brain's ... nose -- do not perceive complex scent mixtures as single ... these nerve cells, or neurons, detect the host of chemical ...
... new generation of pharmaceuticals are studying cellular proteins called ... to turn the expression of those genes on or ... drugs that selectively block the binding of transcription factors ... diseases, and researchers at the University of California, San ...
... suspected, fast help is required. The first step is ... simple, identification of the pathogen; preferably, this test should ... laboratory. Portable miniature biodetection systems that can detect multiple ... American researchers from Lawrence Livermore National Laboratory led by ...
Cached Biology News:Researchers show how brain decodes complex smells 2Cells use mix-and-match approach to tailor regulation of genes 2Encoded metallic nanowires reveal bioweapons 2
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
... Our fastest automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 1.5-4 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Request Info...
Biology Products: